Inaphaea expands PDC Platform with digital avatars and collaborative cancer research.

Inaphaea continues to drive innovation in drug development through its cutting-edge work with Patient-Derived Cells, advanced in-silico modelling, and strategic collaborations.

Read more: https://bit.ly/4ndQYNl

Exclusive licence agreement struck with Dominion Biotech.

Inaphaea is pleased to announce the execution of an exclusive licence agreement with UK-based Dominion Biotech Ltd for our PredictRx® platform.

Find out more about the agreement here: https://bit.ly/3V4Efky
##DrugDiscovery #PDCs

According to Cancer Research UK, over 12,000 cases of head and neck cancer are diagnosed each year.

We offer cells across our biobank of 478 Patient Derived Cancer cells, representing 66 types of cancer, including 11 head and neck PDCs across 7 subtypes (8 with RNA-seq data): https://bit.ly/3tHHLXD

Inaphaea is advancing the characterisation of our most commercially promising Patient-Derived Cells (PDCs). Each model is assessed for expansion potential, growth condition optimisation, and precise cellular composition.

Find out more: https://bit.ly/3tHHLXD
##DrugDiscovery #CancerResearch #PDCs

At Inaphaea, we are dedicated to understanding our drug candidates during the discovery and preclinical phases of development. Our goal is to support decision-making in translational drug development for therapeutic areas within women's health.

View more: https://bit.ly/3SINi9o
##CSAW25

At Inaphaea, we offer cells for purchase and testing services across our biobank of 478 Patient Derived Cell Models, representing 66 cancer indications, including 31 prostate cancer PDCs with RNS-seq data.

View more on our website: https://bit.ly/3SINi9o
##MensHealthWeek #Assays #AssayDevelopment